PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Cash & equivalents declining -26.68% while TRVN's grows 22.79%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy ≥ 1.5x TRVN's -17.14%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Other current assets growth < half of TRVN's 79.02%. David Dodd sees a leaner approach to short-term items.
-27.05%
≥ 1.5x TRVN's -14.88%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.44%
≥ 1.5x TRVN's -2.45%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Above 1.5x TRVN's 1.53%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-5.69%
≥ 1.5x TRVN's -1.93%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
≥ 1.5x TRVN's -12.91%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
9.15%
Less than half of TRVN's 663.03%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Above 1.5x TRVN's -26.02%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of TRVN's -3.04%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Above 1.5x TRVN's -1.97%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of TRVN's -2.65%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-3.34%
≥ 1.5x TRVN's -2.15%. David Dodd sees higher yoy retained profits than competitor.
-6.51%
Less than half of TRVN's -50.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
≥ 1.5x TRVN's -18.42%. David Dodd sees stronger capital base growth than competitor.
-25.21%
≥ 1.5x TRVN's -12.91%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
≥ 1.5x TRVN's -48.70%. David Dodd sees far stronger investment expansions than competitor.
-11.75%
50-75% of TRVN's -16.23%. Bruce Berkowitz sees relatively smaller yoy debt additions.
27.85%
Less than half of TRVN's -224.59%. David Dodd sees better deleveraging or stronger cash buildup than competitor.